| Released | Contributor | Author | Title | Pages | Price |
| 29-Nov-2009 | PriceTarget Research, Inc. |
N/A
| Sanofi-Aventis has a current Overall Rating of A (Highest Rating). | 7 |
$25 |
| 29-Nov-2009 | Freedonia Group Inc, The | The Freedonia Group | Freedonia Focus on Cancer Therapies | 23 |
$500 |
| 29-Nov-2009 | Stock Traders Daily | Thomas H. Kee Jr. | Trading Report for (SNY). A detailed Technical Analysis + Trading Plans for Day Trading, Swing Trading, and Long Term proactive investments in (SNY). | 5 |
$18 |
| 28-Nov-2009 | Standard & Poor's STARS Report |
N/A
| Sanofi-Aventis ADS | 8 |
$35 |
| 27-Nov-2009 | Pechala's Reports | Lubomir Pechala | SANOFI SYNTHELABO ADS (SNY=US) 2-weeks forecast | 1 |
$10 |
| 27-Nov-2009 | Pechala's Reports | Frantisek Pechala | SANOFI SYNTHELABO ADS (SNY=US) 12-months forecast | 1 |
$15 |
| 27-Nov-2009 | Validea |
N/A
| Validea Guru Analysis Report for SNY. Analysis using Validea's interpretation of the published quantitative strategies of well-known Wall Street experts including Peter Lynch, Warren Buffett, Ben Graham and Ken Fisher, among others. | 0 |
$18 |
| 26-Nov-2009 | Ford Investor Services, Inc. |
N/A
| Industry Value Graph: ACL , BAYRY , BMY , LLY , SNY , TEVA -- DRUGS | 3 |
$4 |
| 26-Nov-2009 | Ford Investor Services, Inc. |
N/A
| Value Graph: SANOFI-AVENTIS -- SNY | 1 |
$4 |
| 23-Nov-2009 | Reuters Investment Profile |
N/A
| Sanofi-Aventis SA: Business description, financial summary, 3yr and interim financials, key statistics/ratios and historical ratio analysis. | 12 |
$20 |
1.48% Nasdaq 
Research Reports
